According to the companies the molecule could also be a potential treatment for lupus, lupus nephritis ... Nordisk's recently approved weekly Ozempic (semaglutide), as well as Lilly's well ...

The early data showing transformational impact of autologous cell therapies in lupus and advanced liver ... success of Novo Nordisk’s Wegovy (semaglutide) and other GLP-1 agonists.

Pericarditis recurrence in lupus is more likely — and has a dose ... CHICAGO — Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs.

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).